Systematic literature review of the global burden of illness of mantle cell lymphoma

Abstract

Background: Mantle cell lymphoma (MCL), a rare and aggressive disease, accounts for approximately 5% of all B-cell non-Hodgkin’s lymphomas. Evidence on the burden of this disease, for patients and healthcare providers, is scarce.

Methods: Four systematic literature reviews were developed to identify epidemiological, real-world clinical, economic and humanistic burden data on patients with MCL. Electronic databases searched included MEDLINE and Embase, NHS EED and Econlit.

Results: Eight epidemiological studies, 19 clinical burden, 2 economic impact and 0 quality of life studies were identified. The range of standardized MCL incidence rates was 0.1–1.27/100,000. Overall survival rates of patients at 3 years differed by age at diagnosis (≤65 years: 76–81%, >65 years: 46–64%) and disease stage (stage I: 73–80%, stage IV: 48–53%). Outcomes were poorer in previously treated patients, and those with later stage or blastoid disease, and improved with more recent diagnosis/treatment. Hospitalization is a major contributor to healthcare cost and differs by therapy toxicity.

Conclusions: We identified significant data gaps for many G20 countries for epidemiology, real-world clinical, economic and humanistic burden. These literature reviews demonstrate the ongoing unmet need for MCL patients globally. Future research to further understand the real-world impact of MCL is needed along with new therapeutic options to improve patient outcomes.

Keywords:

• Epidemiology
• survival
• economic burden
• rituximab
• lymphoproliferative disorder

Transparency

Declaration of funding

This study was sponsored by Janssen.

Declaration of financial/other relationships

N.M., J.G., Ch.T. and L.P. have disclosed that they are employees of Janssen. Co.T. has disclosed that he received research support/honoraria from Janssen. M.S.D. has disclosed that he has served as a consultant and advisor for AbbVie, AstraZeneca, Celgene, Gilead, Genentech, Janssen, Merck, Pharmacyclics, TG Therapeutics and Verastem, and received research grants from AstraZeneca, Genentech, Pharmacyclics, TG Therapeutics, Verastem, Bristol-Myers Squibb, MEI and Surface Oncology. J.Q., M.H., P.O’D., and J.O’R. have disclosed that they are employees of ICON plc and have received funding from Janssen to conduct/support this research.

Acknowledgements

None reported.